EpiEndo Pharmaceuticals
PrivateLast Round
Convertible Debt
Jan 7, 2026
Total Funding Raised
$38.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
EpiEndo Pharmaceuticals is a biotechnology company that develops novel non-antibiotic macrolide therapeutics for the treatment of chronic respiratory and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EpiEndo Pharmaceuticals Comparables
Compare EpiEndo Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Areteia Therapeutics | 73% | |
| Alveolus Bio | 71% | |
| Merck & Co., Inc. | 71% |
EpiEndo Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Jan 7, 2026 | ||||
| Series A | Aug 18, 2021 | ||||
| Convertible Debt | Apr 21, 2021 | ||||
| Seed | Dec 18, 2019 | ||||
| Grant | Nov 1, 2019 | ||||
Pre Seed | Jan 17, 2019 |
Key People
Founding team and executive leadership
EpiEndo Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Series A |
| Rannís - The Icelandic Centre for Research | Grant |
| Kvika Asset Management | Series A |
| LSR | Convertible Debt |
| ABC Ventures | Series A |
| Lífeyrissjóður Vestmannaeyja | Convertible Debt |
| Flerie AB | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 17, 2026
Grew 30% QoQ from 10 to 13 employees.
- Jan 7, 2026
Raised $5.84M in convertible debt.
EpiEndo Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about EpiEndo Pharmaceuticals's valuation, stock price, and market status.
Is EpiEndo Pharmaceuticals a public or private company?
EpiEndo Pharmaceuticals is a private company.
What is the current stock price of EpiEndo Pharmaceuticals?
EpiEndo Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks EpiEndo Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EpiEndo Pharmaceuticals worth (valuation)?
Valuation information for EpiEndo Pharmaceuticals is not publicly available.
Can I buy EpiEndo Pharmaceuticals stock?
EpiEndo Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EpiEndo Pharmaceuticals's last funding round?
EpiEndo Pharmaceuticals's most recent funding round was Convertible Debt on January 7, 2026.
Who are the main investors in EpiEndo Pharmaceuticals?
Key investors in EpiEndo Pharmaceuticals include Kvika Asset Management, Flerie AB.
Will EpiEndo Pharmaceuticals IPO soon?
No public IPO plans have been announced for EpiEndo Pharmaceuticals.
How can I track EpiEndo Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in EpiEndo Pharmaceuticals's shares on secondary markets.